Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment
Polsfuss S, Hofmann-Thiel S, Merker M, Krieger D, Niemann S, Rüssmann H, Schönfeld N, Hoffmann H, et al. (9 authors)
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019-09
Abstract
Two new drugs, delamanid and bedaquiline, have recently been approved for treatment of multidrug-resistant and extensively drug-resistant (XDR) tuberculosis. Here, we report a case of clofazimine, bedaquiline, and low-level delamanid resistances acquired during treatment of a patient with XDR tuberculosis.
MeSH terms
- Humans
- Mycobacterium tuberculosis
- Nitroimidazoles
- Oxazoles
- Antitubercular Agents
- Treatment Outcome
- Drug Therapy, Combination
- Microbial Sensitivity Tests
- Drug Resistance, Bacterial
- Middle Aged
- Male
- Extensively Drug-Resistant Tuberculosis
- Diarylquinolines